Humanized Liver Mice Model Market Forecast
- Humanized liver mice model market value is expected to reach US$178 Mn in 2033, up from US$104 Mn recorded in 2024.
- Global humanized liver mice model market is projected to witness a CAGR of 5.6% during the forecast period from 2024 to 2033.
Humanized Liver Mice Model Market Insights
- Humanized mice models have become a promising substitute for conventional animal models.
- The human liver acts as a storage place for several significant pathogens, which cause about half a billion infections and result in between 2.5 and 4.5 million fatalities per year.
- Humanized liver mice models are being used to study the progression of liver diseases and evaluate potential therapeutic interventions
- Several ongoing investigations are focused on developing innovative liver mouse models that closely resemble human physiology.
- Originally, liver mouse models were established through the transplantation of either human liver cells or hepatic cancer cells into immunocompromised mice.
- The outcomes, although, displayed irregularity and lack of dependability. Consequently, researchers created mice with weakened immune systems that naturally destroy their livers.
- The destruction enables human liver cells to grow and replace the original liver, culminating in developing stable models of mice with humanized livers.
- The growth of the humanized mouse and rat model market is primarily driven by the increasing utilization of humanized models in drug discovery research.
- The oncology segment is at the forefront of the expansion of the humanized mouse model industry.
- The growing demand for personalized medicine, and the rising research and development activities in the pharmaceutical and biotechnology industry are the key drivers for the humanized liver mice model market
A Look Back and a Look Forward - Comparative Analysis
The humanized liver mice model market experienced moderate growth before 2023. The market was driven primarily by increasing research on liver diseases, advancements in genetic engineering, and the rising prevalence of liver disorders such as hepatitis and liver cancer. North America largely dominated the market due to substantial investments in biomedical research and robust healthcare infrastructure.
The market for humanized liver mice model is anticipated to witness accelerated growth post-2024. This surge is expected due to technological advancements leading to the development of more reliable and consistent models.
Enhanced capabilities in genetic modifications and better immunodeficient mouse strains that can naturally replace their liver with human liver cells are significant factors contributing to this growth. Also, the increasing number of FDA approvals for hepatitis and other liver disease drugs largely dependent on these models highlights their essential role in drug development.
Key Growth Determinants
- Technological Advancements
The humanized liver mice model market is experiencing significant growth driven by technological advancements. These advancements have developed more sophisticated and reliable models that mimic human liver physiology better. For instance,
Newer models such as PPARalpha and AFC8-based mice demonstrate improved consistency and stability in liver function. The evolution from simple immunodeficient mice implanted with human liver cells to more advanced models that naturally replace their liver with human cells has dramatically enhanced research outcomes.
Innovations facilitate more accurate studies in drug metabolism, liver disease mechanisms, and therapeutic testing, thereby boosting the market's growth potential.
- Rising Prevalence of Liver Diseases
Another critical growth driver for the humanized liver mice model market is the global prevalence of liver diseases. Conditions such as hepatitis B and C, liver cirrhosis, and liver cancer have seen a surge, necessitating extensive research and development of new treatments.
Humanized liver mice models play a crucial role in understanding disease mechanisms and testing potential therapies in a preclinical setting. The global burden of liver diseases, particularly in regions with high endemic rates like Asia and Africa, underscores the demand for these models;
Increased need for effective preclinical testing models is propelling market growth as researchers and pharmaceutical companies invest more in developing and utilizing humanized liver mice models.
- Increasing FDA Approvals for Hepatitis Drugs
The increasing number of FDA approvals for hepatitis drugs is a significant growth driver for the market for humanized liver mice model. The approval process for new drugs requires extensive preclinical testing to ensure safety and efficacy for which humanized liver mice models are invaluable.
The trend of increasing drug approvals, particularly in the treatment of hepatitis, highlights the critical role of these models in drug development.
There was a noticeable increase in approved hepatitis treatments, reflecting the intensified research and validation efforts using humanized liver mice models during the last decade. This trend not only underscores the importance of these models in pharmaceutical research but also stimulates further investment and innovation in this market segment.
Key Growth Barriers
- High Costs of Humanized Liver Mice Models
The high cost of humanized liver mice models presents a significant restraint to market growth. These models, which involve complex genetic modifications and require specialized care, can be prohibitively expensive. For instance,
Immunodeficient mice used for liver studies can cost between $140 and $500 each, while more sophisticated chimeric humanized liver mice models can range from $2,500 to $3,500 per mouse.
High costs of mice are due to the intricate processes involved in developing and maintaining these models, including the use of advanced technologies and the need for specialized shipping containers to ensure their safe transport.
The said financial burden limits the accessibility of these models, particularly for smaller research institutions and companies with limited budgets, thereby hindering wider adoption and humanized liver mice model market expansion.
- Stringent Regulatory Requirements
Stringent regulatory requirements are another major restraint affecting the market for humanized liver mice model. The use of animal models in research is subject to rigorous ethical and regulatory scrutiny, aimed at ensuring humane treatment and justifiable scientific use.
Regulatory frameworks like the 3Rs principle (replace, reduce, and refine) are enforced to minimize the use of animals and encourage the adoption of alternative methods wherever possible. These regulations necessitate extensive documentation and compliance efforts, which can delay research timelines and increase operational costs.
The approval process for using humanized liver mice models in specific studies can be cumbersome and time-consuming, posing significant challenges to researchers and companies. These regulatory hurdles not only slow down the pace of scientific progress but also add to the overall cost and complexity of conducting research, thus restraining the market for humanized liver mice model market growth
Humanized Liver Mice Model Market Trends and Opportunities
- Integration of Advanced Genetic Editing Techniques
One significant trend in the humanized liver mice model market is the integration of advanced genetic editing techniques like CRISPR-Cas9. The technology allows for precise modifications of the mouse genome to create more accurate and reliable humanized liver models.
CRISPR-Cas9 has facilitated the development of models with specific human gene expressions and liver functions closely mimicking human physiology. This trend is driven by the need for better models to study complex liver diseases and test new drugs more effectively.
The precision and efficiency of CRISPR-Cas9 reduce the time and cost associated with developing humanized models, making them more accessible to a broad range of researchers. The adoption of advanced genetic editing tools is expected to enhance the utility of humanized liver mice models in preclinical studies.
As the technologies become more refined and widely adopted, the humanized liver mice model market is likely to see sustained growth and innovation.
- Expansion in Emerging Markets
An exciting opportunity for the humanized liver mice model market lies in the expansion into emerging markets, particularly in regions such as Asia Pacific and Latin America. Governments and private sectors are investing heavily in healthcare infrastructure and research capabilities, providing a robust and secure foundation for the growth of the humanized liver mice model market, ensuring a promising future for our investment.
The high prevalence of hepatitis B and C in these regions underscores the need for effective preclinical models to facilitate the development of new treatments. Expanding into these emerging markets offers companies a pool of opportunities to enter a new revenue stream and diversify their market presence.
Companies can leverage the growing demand and contribute to advancing liver disease research globally by establishing collaborations with local research institutions and investing in regional facilities.
How Does Regulatory Scenario Shape the Humanized Liver Mice Model Market?
Regulatory agencies like the FDA and EMA are increasingly focused on the safety and efficacy of preclinical models used in drug development. Humanized liver mice, models must meet stringent safety standards, ensuring their reliability and accuracy in mimicking human liver function.
Regulatory bodies emphasize ethical considerations and animal welfare in research, promoting the use of humanized liver mice models as they can reduce the number of animals needed by providing more relevant human-like data.
Governments and regulatory bodies often provide funding and grants for research involving advanced preclinical models, including humanized liver mice. Further, efforts are underway to harmonize regulatory standards globally, ensuring that data from humanized liver mice models are accepted across different jurisdictions.
Fairfield’s Ranking Board
Segments Covered in the Report
- Genetic Humanized Model Dominates the Model Type Segmentation
The importance of the genetically humanized mouse model segment lies in its crucial role in expediting drug discovery and development. Pharmaceutical and biotechnology enterprises, as well as research institutions continue to aggressively use genetic humanized mouse models. These models have established themselves as the primary source of revenue for experimental analysis and medication development in the sector.
- Oncology dominates the application segment of the market.
The oncology segment is at the forefront of the expansion of the humanized mouse model industry. Oncology research mostly depends on humanized mouse models to comprehend the biology of cancer, develop novel treatments, and evaluate the efficacy of drugs.
These models enhance the accuracy and reliability of preclinical research by replicating the complex environment of human tumours. The oncology section assumes leadership due to the urgent need for advanced cancer research and the development of therapeutic methods.
The demand for humanized mouse models in this research is expected to be high as long as cancer continues to be a global health issue driving progress and innovation in cancer treatments.
Regional Analysis
- North America to Exhibit Significant Growth
humanized liver mice model market in North America is projected to experience substantial growth. The increasing need for personalized treatment is driving the adoption of humanized mouse models in preclinical research for pharmaceutical development.
Advancements in genetic engineering and genome editing techniques have made it easier to develop humanized mouse models that are more accurate and relevant. Pharmaceutical companies and academic institutions in North America are increasingly utilizing these models to study human diseases and assess potential remedies.
The robust healthcare system and substantial financial investments in biomedical research in the region contribute to the hopeful future of North America's rat and mouse model market.
Fairfield’s Competitive Landscape Analysis
The humanized liver mice model market's competitive landscape is characterized by several key players focusing on innovation and expanding their product portfolios. The key companies invest significantly in research and development to create reliable and efficient humanized models.
Strategic partnerships, mergers, and acquisitions are joint as firms aim to enhance their market position and capabilities. Additionally, the competition is driven by advancements in genetic editing technologies like CRISPR-Cas9, enabling more sophisticated models to be developed. The increasing demand for preclinical testing and the rising prevalence of liver diseases further intensify humanized liver mice model market competition.
Key Market Companies
- Ingenious Targeting Laboratory
- Axenis S.A.S
- Trans Genic Inc.
- Horizon Discovery Group PLC
- HuMurine Technologies
- Champions Oncology Inc.
- Genoway S.A.
- Crown Bioscience Inc.
- Taconic Biosciences Inc.
- The Jackson Laboratory
- Vitalstar Biotechnology Co. Ltd.
Recent Industry Developments
- In January 2022, Taconic Biosciences, Inc. (US) introduced the huNOG-EXL EA (early access) humanized immune system (HIS) mouse.
- In October 2021, The Jackson Laboratory (US) acquired the Research Models & Services (RMS) business of Charles River Laboratories Japan, Inc. (Japan) as a wholly-owned subsidiary.
An Expert’s Eye
- Increasing utilization of humanized liver mice models for accurate human liver function studies creates opportunities in biomedical research.
- The growing prevalence of liver diseases, such as hepatitis, cirrhosis, and liver cancer, caters to the scope of research and development activities.
- Enhanced ability to predict human responses to therapies, improving drug development outcomes.
- The humanized liver mice model market is set for significant expansion with broad applications in biomedical research.
Global Humanized Liver Mice Model Market is Segmented as -
By Model Type
- Genetic
- Cell-based
By Application
- Oncology
- Immunology
- Neuroscience
By End User
- Research Institutes
- Biotech Companies
- Hospitals
By Region
- North America
- Europe
- Asia Pacific
- Latin America
- The Middle East & Africa
1. Executive Summary
1.1. Global Humanized Liver Mice Model Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2024
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter’s Five Forces Analysis
2.5. COVID-19 Impact Analysis
2.5.1. Supply
2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
2.7.1. World Economic Projections
2.8. PESTLE Analysis
3. Global Humanized Liver Mice Model Market Outlook, 2024 - 2033
3.1. Global Humanized Liver Mice Model Market Outlook, by Model, Value (US$ Bn), 2024 - 2033
3.1.1. Key Highlights
3.1.1.1. uPA-SCID
3.1.1.2. FRG KO Mice
3.1.1.3. TK-NOG Mice
3.1.1.4. Other Models
3.2. Global Humanized Liver Mice Model Market Outlook, by Application, Value (US$ Bn), 2024 - 2033
3.2.1. Key Highlights
3.2.1.1. Pharmacokinetics Studies
3.2.1.2. In-vivo Liver Toxicity Testing
3.2.1.3. Drug Metabolism Studies
3.2.1.4. Others
3.3. Global Humanized Liver Mice Model Market Outlook, by End User, Value (US$ Bn), 2024 - 2033
3.3.1. Key Highlights
3.3.1.1. Pharmaceutical Companies
3.3.1.2. Biotechnology Companies
3.3.1.3. Contract Research Organizations (CRO’s)
3.3.1.4. Academic & Research Institutes
3.4. Global Humanized Liver Mice Model Market Outlook, by Region, Value (US$ Bn), 2024 - 2033
3.4.1. Key Highlights
3.4.1.1. North America
3.4.1.2. Europe
3.4.1.3. Asia Pacific
3.4.1.4. Latin America
3.4.1.5. Middle East & Africa
4. North America Humanized Liver Mice Model Market Outlook, 2024 - 2033
4.1. North America Humanized Liver Mice Model Market Outlook, by Model, Value (US$ Bn), 2024 - 2033
4.1.1. Key Highlights
4.1.1.1. uPA-SCID
4.1.1.2. FRG KO Mice
4.1.1.3. TK-NOG Mice
4.1.1.4. Other Models
4.2. North America Humanized Liver Mice Model Market Outlook, by Application, Value (US$ Bn), 2024 - 2033
4.2.1. Key Highlights
4.2.1.1. Pharmacokinetics Studies
4.2.1.2. In-vivo Liver Toxicity Testing
4.2.1.3. Drug Metabolism Studies
4.2.1.4. Others
4.3. North America Humanized Liver Mice Model Market Outlook, by End User, Value (US$ Bn), 2024 - 2033
4.3.1. Key Highlights
4.3.1.1. Pharmaceutical Companies
4.3.1.2. Biotechnology Companies
4.3.1.3. Contract Research Organizations (CRO’s)
4.3.1.4. Academic & Research Institutes
4.3.2. BPS Analysis/Market Attractiveness Analysis
4.4. North America Humanized Liver Mice Model Market Outlook, by Country, Value (US$ Bn), 2024 - 2033
4.4.1. Key Highlights
4.4.1.1. U.S. Humanized Liver Mice Model Market by Model, Value (US$ Bn), 2024 - 2033
4.4.1.2. U.S. Humanized Liver Mice Model Market by Application, Value (US$ Bn), 2024 - 2033
4.4.1.3. U.S. Humanized Liver Mice Model Market by End User, Value (US$ Bn), 2024 - 2033
4.4.1.4. Canada Humanized Liver Mice Model Market by Model, Value (US$ Bn), 2024 - 2033
4.4.1.5. Canada Humanized Liver Mice Model Market by Application, Value (US$ Bn), 2024 - 2033
4.4.1.6. Canada Humanized Liver Mice Model Market by End User, Value (US$ Bn), 2024 - 2033
4.4.2. BPS Analysis/Market Attractiveness Analysis
5. Europe Humanized Liver Mice Model Market Outlook, 2024 - 2033
5.1. Europe Humanized Liver Mice Model Market Outlook, by Model, Value (US$ Bn), 2024 - 2033
5.1.1. Key Highlights
5.1.1.1. uPA-SCID
5.1.1.2. FRG KO Mice
5.1.1.3. TK-NOG Mice
5.1.1.4. Other Models
5.2. Europe Humanized Liver Mice Model Market Outlook, by Application, Value (US$ Bn), 2024 - 2033
5.2.1. Key Highlights
5.2.1.1. Pharmacokinetics Studies
5.2.1.2. In-vivo Liver Toxicity Testing
5.2.1.3. Drug Metabolism Studies
5.2.1.4. Others
5.3. Europe Humanized Liver Mice Model Market Outlook, by End User, Value (US$ Bn), 2024 - 2033
5.3.1. Key Highlights
5.3.1.1. Pharmaceutical Companies
5.3.1.2. Biotechnology Companies
5.3.1.3. Contract Research Organizations (CRO’s)
5.3.1.4. Academic & Research Institutes
5.3.2. BPS Analysis/Market Attractiveness Analysis
5.4. Europe Humanized Liver Mice Model Market Outlook, by Country, Value (US$ Bn), 2024 - 2033
5.4.1. Key Highlights
5.4.1.1. Germany Humanized Liver Mice Model Market by Model, Value (US$ Bn), 2024 - 2033
5.4.1.2. Germany Humanized Liver Mice Model Market by Application, Value (US$ Bn), 2024 - 2033
5.4.1.3. Germany Humanized Liver Mice Model Market by End User, Value (US$ Bn), 2024 - 2033
5.4.1.4. U.K. Humanized Liver Mice Model Market by Model, Value (US$ Bn), 2024 - 2033
5.4.1.5. U.K. Humanized Liver Mice Model Market by Application, Value (US$ Bn), 2024 - 2033
5.4.1.6. U.K. Humanized Liver Mice Model Market by End User, Value (US$ Bn), 2024 - 2033
5.4.1.7. France Humanized Liver Mice Model Market by Model, Value (US$ Bn), 2024 - 2033
5.4.1.8. France Humanized Liver Mice Model Market by Application, Value (US$ Bn), 2024 - 2033
5.4.1.9. France Humanized Liver Mice Model Market by End User, Value (US$ Bn), 2024 - 2033
5.4.1.10. Italy Humanized Liver Mice Model Market by Model, Value (US$ Bn), 2024 - 2033
5.4.1.11. Italy Humanized Liver Mice Model Market by Application, Value (US$ Bn), 2024 - 2033
5.4.1.12. Italy Humanized Liver Mice Model Market by End User, Value (US$ Bn), 2024 - 2033
5.4.1.13. Turkey Humanized Liver Mice Model Market by Model, Value (US$ Bn), 2024 - 2033
5.4.1.14. Turkey Humanized Liver Mice Model Market by Application, Value (US$ Bn), 2024 - 2033
5.4.1.15. Turkey Humanized Liver Mice Model Market by End User, Value (US$ Bn), 2024 - 2033
5.4.1.16. Russia Humanized Liver Mice Model Market by Model, Value (US$ Bn), 2024 - 2033
5.4.1.17. Russia Humanized Liver Mice Model Market by Application, Value (US$ Bn), 2024 - 2033
5.4.1.18. Russia Humanized Liver Mice Model Market by End User, Value (US$ Bn), 2024 - 2033
5.4.1.19. Rest of Europe Humanized Liver Mice Model Market by Model, Value (US$ Bn), 2024 - 2033
5.4.1.20. Rest of Europe Humanized Liver Mice Model Market by Application, Value (US$ Bn), 2024 - 2033
5.4.1.21. Rest of Europe Humanized Liver Mice Model Market by End User, Value (US$ Bn), 2024 - 2033
5.4.2. BPS Analysis/Market Attractiveness Analysis
6. Asia Pacific Humanized Liver Mice Model Market Outlook, 2024 - 2033
6.1. Asia Pacific Humanized Liver Mice Model Market Outlook, by Model, Value (US$ Bn), 2024 - 2033
6.1.1. Key Highlights
6.1.1.1. uPA-SCID
6.1.1.2. FRG KO Mice
6.1.1.3. TK-NOG Mice
6.1.1.4. Other Models
6.2. Asia Pacific Humanized Liver Mice Model Market Outlook, by Application, Value (US$ Bn), 2024 - 2033
6.2.1. Key Highlights
6.2.1.1. Pharmacokinetics Studies
6.2.1.2. In-vivo Liver Toxicity Testing
6.2.1.3. Drug Metabolism Studies
6.2.1.4. Others
6.3. Asia Pacific Humanized Liver Mice Model Market Outlook, by End User, Value (US$ Bn), 2024 - 2033
6.3.1. Key Highlights
6.3.1.1. Pharmaceutical Companies
6.3.1.2. Biotechnology Companies
6.3.1.3. Contract Research Organizations (CRO’s)
6.3.1.4. Academic & Research Institutes
6.3.2. BPS Analysis/Market Attractiveness Analysis
6.4. Asia Pacific Humanized Liver Mice Model Market Outlook, by Country, Value (US$ Bn), 2024 - 2033
6.4.1. Key Highlights
6.4.1.1. China Humanized Liver Mice Model Market by Model, Value (US$ Bn), 2024 - 2033
6.4.1.2. China Humanized Liver Mice Model Market by Application, Value (US$ Bn), 2024 - 2033
6.4.1.3. China Humanized Liver Mice Model Market by End User, Value (US$ Bn), 2024 - 2033
6.4.1.4. Japan Humanized Liver Mice Model Market by Model, Value (US$ Bn), 2024 - 2033
6.4.1.5. Japan Humanized Liver Mice Model Market by Application, Value (US$ Bn), 2024 - 2033
6.4.1.6. Japan Humanized Liver Mice Model Market by End User, Value (US$ Bn), 2024 - 2033
6.4.1.7. South Korea Humanized Liver Mice Model Market by Model, Value (US$ Bn), 2024 - 2033
6.4.1.8. South Korea Humanized Liver Mice Model Market by Application, Value (US$ Bn), 2024 - 2033
6.4.1.9. South Korea Humanized Liver Mice Model Market by End User, Value (US$ Bn), 2024 - 2033
6.4.1.10. India Humanized Liver Mice Model Market by Model, Value (US$ Bn), 2024 - 2033
6.4.1.11. India Humanized Liver Mice Model Market by Application, Value (US$ Bn), 2024 - 2033
6.4.1.12. India Humanized Liver Mice Model Market by End User, Value (US$ Bn), 2024 - 2033
6.4.1.13. Southeast Asia Humanized Liver Mice Model Market by Model, Value (US$ Bn), 2024 - 2033
6.4.1.14. Southeast Asia Humanized Liver Mice Model Market by Application, Value (US$ Bn), 2024 - 2033
6.4.1.15. Southeast Asia Humanized Liver Mice Model Market by End User, Value (US$ Bn), 2024 - 2033
6.4.1.16. Rest of Asia Pacific Humanized Liver Mice Model Market by Model, Value (US$ Bn), 2024 - 2033
6.4.1.17. Rest of Asia Pacific Humanized Liver Mice Model Market by Application, Value (US$ Bn), 2024 - 2033
6.4.1.18. Rest of Asia Pacific Humanized Liver Mice Model Market by End User, Value (US$ Bn), 2024 - 2033
6.4.2. BPS Analysis/Market Attractiveness Analysis
7. Latin America Humanized Liver Mice Model Market Outlook, 2024 - 2033
7.1. Latin America Humanized Liver Mice Model Market Outlook, by Model, Value (US$ Bn), 2024 - 2033
7.1.1. Key Highlights
7.1.1.1. uPA-SCID
7.1.1.2. FRG KO Mice
7.1.1.3. TK-NOG Mice
7.1.1.4. Other Models
7.2. Latin America Humanized Liver Mice Model Market Outlook, by Application, Value (US$ Bn), 2024 - 2033
7.2.1. Key Highlights
7.2.1.1. Pharmacokinetics Studies
7.2.1.2. In-vivo Liver Toxicity Testing
7.2.1.3. Drug Metabolism Studies
7.2.1.4. Others
7.3. Latin America Humanized Liver Mice Model Market Outlook, by End User, Value (US$ Bn), 2024 - 2033
7.3.1. Key Highlights
7.3.1.1. Pharmaceutical Companies
7.3.1.2. Biotechnology Companies
7.3.1.3. Contract Research Organizations (CRO’s)
7.3.1.4. Academic & Research Institutes
7.3.2. BPS Analysis/Market Attractiveness Analysis
7.4. Latin America Humanized Liver Mice Model Market Outlook, by Country, Value (US$ Bn), 2024 - 2033
7.4.1. Key Highlights
7.4.1.1. Brazil Humanized Liver Mice Model Market by Model, Value (US$ Bn), 2024 - 2033
7.4.1.2. Brazil Humanized Liver Mice Model Market by Application, Value (US$ Bn), 2024 - 2033
7.4.1.3. Brazil Humanized Liver Mice Model Market by End User, Value (US$ Bn), 2024 - 2033
7.4.1.4. Mexico Humanized Liver Mice Model Market by Model, Value (US$ Bn), 2024 - 2033
7.4.1.5. Mexico Humanized Liver Mice Model Market by Application, Value (US$ Bn), 2024 - 2033
7.4.1.6. Mexico Humanized Liver Mice Model Market by End User, Value (US$ Bn), 2024 - 2033
7.4.1.7. Argentina Humanized Liver Mice Model Market by Model, Value (US$ Bn), 2024 - 2033
7.4.1.8. Argentina Humanized Liver Mice Model Market by Application, Value (US$ Bn), 2024 - 2033
7.4.1.9. Argentina Humanized Liver Mice Model Market by End User, Value (US$ Bn), 2024 - 2033
7.4.1.10. Rest of Latin America Humanized Liver Mice Model Market by Model, Value (US$ Bn), 2024 - 2033
7.4.1.11. Rest of Latin America Humanized Liver Mice Model Market by Application, Value (US$ Bn), 2024 - 2033
7.4.1.12. Rest of Latin America Humanized Liver Mice Model Market by End User, Value (US$ Bn), 2024 - 2033
7.4.2. BPS Analysis/Market Attractiveness Analysis
8. Middle East & Africa Humanized Liver Mice Model Market Outlook, 2024 - 2033
8.1. Middle East & Africa Humanized Liver Mice Model Market Outlook, by Model, Value (US$ Bn), 2024 - 2033
8.1.1. Key Highlights
8.1.1.1. uPA-SCID
8.1.1.2. FRG KO Mice
8.1.1.3. TK-NOG Mice
8.1.1.4. Other Models
8.2. Middle East & Africa Humanized Liver Mice Model Market Outlook, by Application, Value (US$ Bn), 2024 - 2033
8.2.1. Key Highlights
8.2.1.1. Pharmacokinetics Studies
8.2.1.2. In-vivo Liver Toxicity Testing
8.2.1.3. Drug Metabolism Studies
8.2.1.4. Others
8.3. Middle East & Africa Humanized Liver Mice Model Market Outlook, by End User, Value (US$ Bn), 2024 - 2033
8.3.1. Key Highlights
8.3.1.1. Pharmaceutical Companies
8.3.1.2. Biotechnology Companies
8.3.1.3. Contract Research Organizations (CRO’s)
8.3.1.4. Academic & Research Institutes
8.3.2. BPS Analysis/Market Attractiveness Analysis
8.4. Middle East & Africa Humanized Liver Mice Model Market Outlook, by Country, Value (US$ Bn), 2024 - 2033
8.4.1. Key Highlights
8.4.1.1. GCC Humanized Liver Mice Model Market by Model, Value (US$ Bn), 2024 - 2033
8.4.1.2. GCC Humanized Liver Mice Model Market by Application, Value (US$ Bn), 2024 - 2033
8.4.1.3. GCC Humanized Liver Mice Model Market by End User, Value (US$ Bn), 2024 - 2033
8.4.1.4. South Africa Humanized Liver Mice Model Market by Model, Value (US$ Bn), 2024 - 2033
8.4.1.5. South Africa Humanized Liver Mice Model Market by Application, Value (US$ Bn), 2024 - 2033
8.4.1.6. South Africa Humanized Liver Mice Model Market by End User, Value (US$ Bn), 2024 - 2033
8.4.1.7. Egypt Humanized Liver Mice Model Market by Model, Value (US$ Bn), 2024 - 2033
8.4.1.8. Egypt Humanized Liver Mice Model Market by Application, Value (US$ Bn), 2024 - 2033
8.4.1.9. Egypt Humanized Liver Mice Model Market by End User, Value (US$ Bn), 2024 - 2033
8.4.1.10. Nigeria Humanized Liver Mice Model Market by Model, Value (US$ Bn), 2024 - 2033
8.4.1.11. Nigeria Humanized Liver Mice Model Market by Application, Value (US$ Bn), 2024 - 2033
8.4.1.12. Nigeria Humanized Liver Mice Model Market by End User, Value (US$ Bn), 2024 - 2033
8.4.1.13. Rest of Middle East & Africa Humanized Liver Mice Model Market by Model, Value (US$ Bn), 2024 - 2033
8.4.1.14. Rest of Middle East & Africa Humanized Liver Mice Model Market by Application, Value (US$ Bn), 2024 - 2033
8.4.1.15. Rest of Middle East & Africa Humanized Liver Mice Model Market by End User, Value (US$ Bn), 2024 - 2033
8.4.2. BPS Analysis/Market Attractiveness Analysis
9. Competitive Landscape
9.1. By End User vs by Application Heat map
9.2. Manufacturer vs by Application Heatmap
9.3. Company Market Share Analysis, 2024
9.4. Competitive Dashboard
9.5. Company Profiles
9.5.1. Hera BioLabs
9.5.1.1. Company Overview
9.5.1.2. Product Portfolio
9.5.1.3. Financial Overview
9.5.1.4. Business Strategies and Development
9.5.2. Taconic Biosciences, Inc.
9.5.2.1. Company Overview
9.5.2.2. Product Portfolio
9.5.2.3. Financial Overview
9.5.2.4. Business Strategies and Development
9.5.3. Beijing Vitalstar Biotechnology Co., Ltd.
9.5.3.1. Company Overview
9.5.3.2. Product Portfolio
9.5.3.3. Financial Overview
9.5.3.4. Business Strategies and Development
9.5.4. Yecuris Corporation
9.5.4.1. Company Overview
9.5.4.2. Product Portfolio
9.5.4.3. Financial Overview
9.5.4.4. Business Strategies and Development
9.5.5. PhoenixBio Group
9.5.5.1. Company Overview
9.5.5.2. Product Portfolio
9.5.5.3. Financial Overview
9.5.5.4. Business Strategies and Development
9.5.6. In-Vivo Science Inc.
9.5.6.1. Company Overview
9.5.6.2. Product Portfolio
9.5.6.3. Financial Overview
9.5.6.4. Business Strategies and Development
9.5.7. The Jackson Laboratory
9.5.7.1. Company Overview
9.5.7.2. Product Portfolio
9.5.7.3. Financial Overview
9.5.7.4. Business Strategies and Development
9.5.8. University of Massachusetts Medical School(Mueller Lab)
9.5.8.1. Company Overview
9.5.8.2. Product Portfolio
9.5.8.3. Financial Overview
9.5.8.4. Business Strategies and Development
9.5.9. Oncodesign
9.5.9.1. Company Overview
9.5.9.2. Product Portfolio
9.5.9.3. Financial Overview
9.5.9.4. Business Strategies and Development
9.5.10. University of Nebraska Medical Center
9.5.10.1. Company Overview
9.5.10.2. Product Portfolio
9.5.10.3. Financial Overview
9.5.10.4. Business Strategies and Development
10. Appendix
10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations
|
BASE YEAR |
HISTORICAL DATA |
FORECAST PERIOD |
UNITS |
|||
 |
2023 |
 |
2019 - 2023 |
 |
2024 - 2033 |
Value: US$ Million |
|
REPORT FEATURES |
DETAILS |
|
Model Type Coverage |
|
|
Application Type Coverage |
|
|
End User Coverage |
|
|
Geographical Coverage |
|
|
Leading Companies |
|
|
Report Highlights |
Key Market Indicators, Macro-micro economic impact analysis, Technological Roadmap, Key Trends, Driver, Restraints, and Future Opportunities & Revenue Pockets, Porter’s 5 Forces Analysis, Historical Trend (2019-2021), Market Estimates and Forecast, Market Dynamics, Industry Trends, Competition Landscape, Category, Region, Country-wise Trends & Analysis, COVID-19 Impact Analysis (Demand and Supply Chain) |
Quality assured
